Outset Medical

Outset Medical, Inc. is a medical technology company, which provides dialysis solutions to patients and healthcare providers. Its product Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Outset Medical reports robust Q4 performance and eyes home market growth

Outset Medical's Q4 performance showcased strong growth in Tablo Consoles and revenue, with a focus on expanding home dialysis programs and improving patient experience.
The company's strategic initiatives to manage expenses, reduce inventory levels, and enhance cash flow position it for sustainable growth and operational efficiency.
Challenges lie in meeting revenue guidance, sustaining margin expansion, and optimizing sales force efficiency, while opportunities exist in expanding home programs and leveraging partnerships for growth.
Overall, Outset Medical's performance reflects a balanced approach to growth, operational excellence, and strategic positioning in the dialysis market.

Outset Medical excels in Q1 2023, eyes home dialysis growth

Outset Medical's Q1 2023 performance was robust, with revenue growth and margin expansion surpassing expectations.
The company's focus on innovation, margin improvement, and market expansion positions it well for sustained growth.
Challenges in managing expenses and cash burn require attention, but opportunities in home dialysis and premium offerings offer avenues for future growth.

Outset Medical reports strong Q2 results, eyes sustained growth

Outset Medical delivered robust Q2 2023 results, focusing on revenue growth, margin improvement, and commercial progress in acute and home markets. The company reiterated its revenue guidance for 2023 and expressed confidence in Q4 growth driven by business visibility and network effects.
Despite facing challenges related to FDA compliance and market expansion, Outset Medical showcased strengths in customer base expansion, service margin improvement, and market acceptance of Tablo. The company's commitment to patient and provider autonomy underpins its dedication to delivering quality healthcare solutions.
With opportunities to present economic analysis data, drive utilization in acute care settings, and capitalize on Tablo's value proposition, Outset Medical is poised for sustained growth in 2024. Leveraging market trends and addressing challenges will be key to the company's success in the evolving healthcare landscape.

Outset Medical reports Q3 growth, eyes strategic expansion opportunities

Outset Medical's Q3 performance reflects steady revenue growth and margin expansion, with a focus on strategic growth initiatives.
The company's strengths lie in Tablo's success in both acute and home markets, positioning it for future growth and market expansion.
Challenges include navigating competitive pressures and achieving profitability amidst evolving market dynamics, while opportunities exist in market penetration and strategic growth avenues.

Outset Medical reports strong Q4 earnings, eyes growth opportunities

Outset Medical's Q4 performance was strong, with revenue meeting expectations and showing growth, driven by recurring revenue and expense reductions.
The company's strengths lie in wide market presence, valuable software offerings, unique technology, and effective competitive response strategies.
Challenges include deepening patient census, competitive pressures, transitioning to home dialysis, and maintaining cost efficiency and quality of care.
Opportunities for Outset Medical include revenue growth through software, the shift towards home dialysis, Medicare Advantage support, and payer discussions.

Outset Medical reports Q1 revenue miss, focuses on profitability goals

Outset Medical's Q1 performance showed progress despite revenue challenges, with a focus on cost reduction and profitability.
Strengths lie in successful partnerships, nationwide coverage, and gross margin improvement.
Challenges include revenue impact from delays and the need to balance restructuring with customer experience.
Opportunities include revenue growth in Q2, pipeline expansion, and leveraging technology advantage for innovation.

Outset Medical faces sales transformation challenges amidst revenue softness

Outset Medical's Q2 2024 earnings call highlighted revenue softness from console sales but strength in treatment sales and gross margin performance. The company is undergoing a sales transformation to target mainstream enterprise adopters and expects revenue of approximately $110 million for the year.

Outset Medical reports robust Q3 results and eyes growth opportunities

Outset Medical's Q3 performance showcased revenue growth, margin expansion, and strategic focus on profitability.
While facing challenges in maintaining margins, the company remains optimistic about growth opportunities in various market segments.
Executives highlighted the importance of a conservative outlook and emphasized the strength of their order pipeline and sales transformation progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Outset Medical, Inc. engages in the provision of dialysis solutions to patients and healthcare providers. Its product, Tablo Hemodialysis System (Tablo), offers technological advancement enabling novel, transformational dialysis care in acute and home settings. The company was founded in 2003 and is headquartered in San Jose, CA.

Boston Omaha

Little-known Boston Omaha is a quiet compounder, while Outset Medical's dialysis treatment could change millions of lives.

Supercharged Returns: 2 Growth Stocks That Could Turn $1,000 Into $10,000

SAN JOSE, Calif.--( BUSINESS WIRE )--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15am PT / 2:15pm ET.

Outset Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference

Outset Medical, Inc. revised FY22 guidance to the upside, with management forecasts now ahead of consensus. Home hemodialysis market is poised for ongoing growth into 2028.

Outset Medical: Revising To Buy, Market Dynamics, Guidance As Catalysts (Upgrade)

SAN JOSE, Calif.--( BUSINESS WIRE )--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a virtual panel discussion at the BofA Securities Home Care Conference on Tuesday, December 6, 2022 at 12:10pm PT / 3:10pm ET.

Outset Medical to Present at the BofA Securities Home Care Conference

Inmode Ltd

These companies are disrupting the healthcare industry and growing rapidly.

2 No-Brainer Stocks to Buy Now That Could Soar in 2023

SAN JOSE, Calif.--( BUSINESS WIRE )--Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced it ranked 33 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America, now in its 28th year. Outset revenue grew 5,000 percent to $103 million between 2018 and 2021.

Outset Medical Ranked Number 33 Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

Axon Enterprise

If you like gains of 15% to 30%, these stocks are for you.

2 Big Stock Winners From a Horrible Day on Wall Street

Outset Medical, Inc. (NASDAQ:OM ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Jim Mazzola – Vice President-Investor Relations Leslie Trigg – Chair and Chief Executive Officer Nabeel Ahmed – Chief Financial Officer Conference Call Participants Travis Steed – BofA Securities Joshua Jennings – Cowen Phil Coover – Goldman Sachs Rick Wise – Stifel Suraj Kalia – Oppenheimer Drew Ranieri – Morgan Stanley Operator Good day and thank you for standing by. Welcome to Outset Medical Third Quarter 2022 Earnings Conference Call.

Outset Medical, Inc. (OM) Q3 2022 Earnings Call Transcript

Outset Medical Reports Third Quarter 2022 Financial Results

Outset Medical Secures Up To $300 Million in Debt Financing

Outset Medical Presenting Research on Human Factors Testing, Home Dialysis Patient Experience and More During ASN Kidney Week 2022

Outset Medical to Report Third Quarter 2022 Financial Results Tuesday, November 8, 2022

Outset Medical continued to face a multivariate equation of headwinds last quarter. The stock has continued its long-term downtrend whilst technical indicators aren't signalling a reversal any time soon.

Outset Medical: Tablo Ship Hold A Key Overhang To Unlock Risk Capital

Did you lose money on investments in Outset Medical? If so, please visit Outset Medical, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.New York, New York--(Newsfile Corp.

OUTSET MEDICAL, INC. (OM) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Outset Medical, Inc. (OM)

NEW YORK , Sept. 6, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM) alleging that the Company violated federal securities laws.

OM ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 6, 2022 in the Class Action Filed on Behalf of Outset Medical, Inc. Shareholders

New York, New York--(Newsfile Corp. - September 6, 2022) -  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the "Class Period"), of the important September 6, 2022 lead plaintiff deadline.

OM FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Outset Medical, Inc. Investors to Secure Counsel Before Important September 6 Deadline in Securities Class Action - OM

Los Angeles, California--(Newsfile Corp. - September 6, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Outset Medical, Inc. with Losses of $500,000 to Contact the Firm

NEW YORK , Sept. 5, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the "Class Period"), of the important September 6, 2022 lead plaintiff deadline.

OM DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors With Losses to Secure Counsel Before Important September 6 Deadline in Securities Class Action - OM

New York, New York--(Newsfile Corp. - September 5, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Outset securities between September 15, 2020, and June 13, 2022, inclusive (the "Class Period").

Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Outset Medical, Inc. (OM) Investors of Class Action and Last Few Hours to Actively Participate

Los Angeles, California--(Newsfile Corp. - September 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Outset Medical, Inc. with Losses of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - September 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the "Class Period"), of the important September 6, 2022 lead plaintiff deadline.

OM TUESDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors With Losses to Secure Counsel Before Important September 6 Deadline in Securities Class Action - OM

NEW YORK , Sept. 2, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Outset Medical, Inc. (NASDAQ: OM).

OM SHAREHOLDER ALERT: Jakubowitz Law Reminds Outset Medical Shareholders of a Lead Plaintiff Deadline of September 6, 2022

New York, New York--(Newsfile Corp. - September 1, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Outset Medical, Inc. (NASDAQ: OM) between September 15, 2020 and June 13, 2022, both dates inclusive (the "Class Period"), of the important September 6, 2022 lead plaintiff deadline.

OM FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Outset Medical, Inc. Investors With Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - OM

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 6, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM) common stock between September 15, 2020 and June 13, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On May 4, 2022, after the market closed, Outset disclos

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outset Medical, Inc. (OM)

Los Angeles, California--(Newsfile Corp. - September 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Outset Medical, Inc. ("Outset" or "the Company") (NASDAQ: OM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

News for Outset Medical Stock (OM)